Pfenex — Investor Presentation (February 2018)
21 slides from Pfenex's investor presentation, Feb 27, 2018
Slide 1: Exhibit 99.1
NYSE American: PFNX Exhibit 99.1
Slide 2: Forward-looking statements
This presentation, including the accompanying oral presentation (the “Presentation”), includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently avai
Slide 3: Overview
Clinical stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs Advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars Key pipeline products drive significant near t
Slide 4: Pfenex Expression Technology Platform
Pfenex Expression Technology® Platform based on Pseudomonas fluorescens Proprietary Platform 60+ partnerships, incl. 12 of 15 top pharma companies, resulting in multiple existing royalty-bearing partnerships plus broad wholly-owned portfolio Validated Scalable Therapeutic equivalents, vaccines, anti
Slide 5: Proprietary Platform
Proprietary Platform Pfenex Expression Technology® Robust Analytics State of the art analytical capability ensures high quality & targeted process optimization 3 Advanced Strain Engineering 1 Accelerated Development 2 Integrated and highly automated development approach enables rapid and predictable
Slide 6: Pipeline Highlights
Products in Development Pipeline Highlights Existing USG THIRD-PARTY Anthrax Vaccine Contract 5 Years - $911MM3 $1.7B Reference drug 2017 Global sales2 $3.3B $4.5B $0.2B PF7081 Teriparatide (Forteo®) PF582 Ranibizumab (Lucentis®) PF529 Pegfilgrastim (Neulasta®) PF690 Pegaspargase (Oncaspar®) Jazz Pa
Slide 7: Focused Execution for 2018
Focused Execution for 2018 Focus on and deliver key programs 1 Selectively expand and maximize our Pfenex Expression Technology® based partnered portfolio 2 Drive development and commercial partnerships 3 Targeted and lean execution 4 Strong base for success Anticipated Key Milestones PF708 (teripar
Slide 8: Strong Financial Position
Strong Financial Position Financials Shares Outstanding 23.5 million as of September 30, 2017 Total Cash $48.6 million as of September 30, 2017 $18.5 million Jazz process development and amendment signing milestone Q4’17 Runway Cash position that supports key milestones and >12 months runway
Slide 9: Experienced Management
Evert (Eef) Schimmelpennink (Aug 2017) CEO, President, Director and Secretary Patrick K. Lucy Chief Business Officer Hubert Chen Chief Medical & Scientific Officer Senior Management Board of Directors Experienced Management New and Established Leadership Aligned to Drive Growth John Taylor Dennis Fe
Slide 10: Products in Development
Products in Development
Slide 11: Forteo (teriparatide) PF708 bioequivalence
Forteo® (teriparatide) rDNA protein and pen combination product Indicated for treatment of high fracture risk osteoporosis 2017 global sales of $1.7B of reference drug4 Pfenex achieved: bioequivalence in healthy subjects high titer protein production competitive cost of goods functionally equivalent
Slide 12: Phase 3 osteoporosis trial nearing completion
Phase 3 osteoporosis trial nearing completion Primary endpoint immunogenicity Secondary endpoints pharmacokinetics, bone mineral density and bone turnover markers Phase 3 PK profiles show comparability between PF708 and Forteo® Complements Phase 1 bioequivalence results in healthy subjects Products
Slide 13: PF708: Therapeutic Equivalent Candidate to Forteo
Products in Development PF708: Therapeutic Equivalent Candidate to Forteo® Pfenex PF708 PF708 (teriparatide [rDNA] injection) Key upcoming program milestones: Primary endpoint of immunogenicity anticipated in Q2’18 505(b)(2) NDA filing expected Q3’18 Projected commercial US launch Q3’19 Strong IP st
Slide 14: Jazz Pharmaceuticals/Pfenex Partnership
Pfenex granted Jazz worldwide rights to develop and commercialize multiple Pfenex Expression Platform based hematology/oncology product candidates Key program highlights: Up to $224.5MM in upfront and potential milestone payments including up to $84.5MM non-sales related Tiered royalties on net sale
Slide 15: Px563L/RPA563: Next Generation Anthrax Vaccine Candidates
Awarded BARDA contract in August 2015 Key program highlights: US Government funds up to $143.5MM of advanced development Potential procurement contract if within 10 years of FDA approval US administration has demonstrated strong support for development of medical countermeasures Current sole sourced
Slide 16: Px563L/RPA563: Next Generation Anthrax Vaccine Candidates
Anthrax recombinant Protective Antigen (rPA) vaccine candidates: Demonstrated long term stability data from showing maintenance of high purity at 5°C at 40 months Phase 1a Day 70 analysis demonstrated that Px563L and RPA563 were well-tolerated and afforded immunogenicity protection with fewer doses
Slide 17: PF582: Biosimilar to Lucentis
Lucentis® (ranibizumab) main indication neovascular (wet) age-related macular degeneration Global Lucentis® market was $3.3 billion in 20177 Latest known composition of matter expected patent expiry: USA 2020; EU 20228 Phase 1/2 first-in-human study completed: Met primary objective of demonstrating
Slide 18: PF529: Biosimilar Candidate to Neulasta
Neulasta® (pegfilgrastim) is indicated for the prevention of febrile neutropenia in patients receiving cytotoxic chemotherapy Neulasta® global sales in 2017: $4.5 billion9 Production process developed and extensive analytical comparability to reference product completed Successfully completed a Bios
Slide 19: Proven success developing complex therapeutic proteins
Proven success developing complex therapeutic proteins with Pfenex Expression Technology® platform Proven Platform Near-term Catalysts Strong Cash PF708 immunogenicity study results Q2’18 and NDA submission Q3’18; Continuous advancement of development milestones in Jazz partnership programs; Potenti
Slide 20: References
References 1. Being developed via the 505(b)(2) pathway in the United States 2 Based on publicly available 2017 sales data for the third party branded pharmaceutical company 3 https://www.sec.gov/Archives/edgar/data/1367644/000136764416000084/form8kearningsq3q2016.htm 4 Eli Lilly Q4’17 and Full Year
Slide 21: NYSE American: PFNX
NYSE American: PFNX Corporate Presentation